Grupele de risc pentru boala pneumococică

Creșterea riscului de boală pneumococică invazivă (BPI) comparativ cu populația generală
* 2.5 [2.0–3.0], 4.9 [4.0–6.0]. USA, 2008–2014, total n= 3.5 milioane, totalul cazurilor de BPI n=1549.1
† Vârsta cuprinsă între 18-64 de ani. 5.8 [4.99–6.75]. Olanda 2008–2012, total n= 4.2 milioane, Cazuri de BPI cu BCC 266/960.2
‡ Vârsta cuprinsă între 18-64 de ani. Olanda 2008–2012, total n= 4.2 milioane, cazuri de BPI cu BPC 207/960.2
§ Vârsta cuprinsă între 18-64 de ani. 6.3 [5.19–7.73]. Olanda 2008–2012, total n= 4.2 milioane, BPI asociată diabetului 123/960.2
¶ Vârsta cuprinsă între 18-64 de ani. Olanda 2008–2012, total n= 4.2 milioane, cazuri de BPI asociat imunosupresiei 121/960.2
|| Alcoolism 1.6 [1.2–2.0]; tabagism 1.6 [1.4–1.8]. SUA, 2008–2014, total n= 3.5 milioane, totalul cazurilor de BPI n=1549.1
** 2.1 [1.5–2.8]. SUA, 2008–2014, total n= 3.5 milioane, totalul cazurilor de BPI n=1549.1
†† 6.4 [1,6–16.7]. SUA, 2008–2014, n= 3.5 milioane, totalul cazurilor de BPI n=1549.1
‡‡ 2.2 [1.9–2.5], 2.9 [2.5–3.5], 5.2 [4.4–6.1]. SUA, 2008–2014, total n= 3.5 milioane, totalul cazurilor de BPI n=1549.1
BCC, Boală cardiacă cronică
BPC, Boală pulmonară cronică
BPI, boală pneuomococică invazivă
LCR, Lichid cefalorahidian
SUA, Statele Unite ale Americii
REFERINȚE:
  1. Baxter R, Yee A, Aukes L, et al. Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults. Vaccine. 2016;34(36):4293-4297.
  2. Wagenvoort GH, Knol MJ, de Melker HE, et al. Risk and outcomes of invasive pneumococcal disease in adults with underlying conditions in the post-PCV7 era, The Netherlands. Vaccine. 2016;34(3):334-340.
  3. Kahue CN, Sweeney AD, Carlson ML, Haynes DS. Vaccination recommendations and risk of meningitis following cochlear implantation. Curr Opin Otolaryngol Head Neck Surg. 2014;22(5):359-366.
  4. Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices [published correction appears in MMWR Morb Mortal Wkly Rep. 2020 Jan 03;68(5152):1195]. MMWR Morb Mortal Wkly Rep. 2019;68(46):1069-1075
  5. Park SB, Kim HJ, Cheong HJ. Environmental factors which can affect the burden of pneumococcal disease and the immune response to pneumococcal vaccines: the need for more precisely delineated vaccine recommendations. Expert Rev Vaccines. 2019;18(6):587-596